Wordt geladen...

Chronic myelogenous leukemia on target

Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off‐target effects, treatment‐induced drug resistance, and the limited effect of the...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Med
Hoofdauteurs: Némethová, Veronika, Rázga, Filip
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2018
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6051163/
https://ncbi.nlm.nih.gov/pubmed/29905026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1604
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!